Quintrio
Home

Stock overview

Optimi Health Corp. Common Shares

OPTH

Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The company has one reportable operating segment being that of the farming, processing, and distribution of raw mushroom biomass. It also intends to cultivate, extract, process, and distribute strains of fungi products at its facilities located in Princeton, British Columbia.

Last trade $2.07
Day change -$0.08 (-3.72%)
Day range $1.97 – $2.20
Volume 15,939
Market cap $12M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for OPTH.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for OPTH.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Optimi Health to Present at the ThinkEquity Conference

Optimi Health Corp., a commercial-stage pharmaceutical manufacturer of psychedelic drug products, announced its participation in the ThinkEquity Conference on October 15, 2026, in New York City. Management will present a corporate overview and meet with investors. The company is a Health Canada-licensed manufacturer producing GMP-grade MDMA and psilocybin products for mental health therapies.

Benzinga

SRx Health Solutions Closes EMJX Acquisition and Launches AI-Driven Platform Strategy Under New Name and Brand, SRX Global, Focused on Investments in High-Conviction Operating Companies and Assets

SRx Health Solutions has completed its acquisition of EMJ Crypto Technologies (EMJX) and rebranded as SRX Global Inc. The company is launching an AI-driven platform strategy focused on capital allocation into high-conviction operating companies and assets. The merged entity will be led by Kent Cunningham as CEO and Eric Jackson as President and Head of Asset Management, with initial investments in companies including Astro Capital, Opendoor Technologies, Uber Technologies, and Optimi Health Corp.

Benzinga

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Optimi Health Corp. announced the completion of two standardized microdose psilocybin finished drug products at 1mg and 2mg dosages for clinical research organizations. The products offer consistent, validated doses derived from naturally sourced psilocybin, extending Optimi's existing 5mg formulation currently prescribed for treatment-resistant depression in Australia. All production is conducted in-house at Optimi's GMP-compliant facility in British Columbia, Canada.

Benzinga

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Optimi Health has completed a GMP production run of its 5mg psilocybin finished drug product for commercial use in Australia to treat treatment-resistant depression. The company manufactures the entire product in-house at its Health Canada-licensed facility, from biomass cultivation through final packaging. Additional product from the run will support clinical trials in the United States and Europe.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
May 20, 20261-for-30reverse split